Tristel plc
("Tristel" or the "Company")
Confirmation of CEO Transition and Directorate Change
Tristel plc (AIM: TSTL), the manufacturer of infection prevention products, confirms that Matt Sassone has today assumed his position of CEO of Tristel, following Paul Swinney's retirement, as previously announced on 10 June 2024.
The Company also announces that Bart Leemans will step down from the Tristel Board as an Executive Director. He will remain with the business and continue to focus his efforts on the French market in his capacity as Managing Director, Tristel SAS. There are no current plans to replace Bart on the Tristel Board.
Bart was appointed in November 2018 following Tristel's acquisition of his business, the Ecomed Group, the Company's then distributor in Belgium, the Netherlands and France. The French market continues to represent significant untapped growth potential for the Company; sales in France during the year ended 30 June 2024 were £3.0 million, approximately 7% of the Group's total of £41.9 million, compared with 13% of Group sales generated in Germany and 39% in the UK.
Bruno Holthof, Chair of Tristel, commented: "I would like to welcome Matt to our Company, and also thank Bart for his contribution to the Board during his tenure. He has brought with him great entrepreneurial spirit and drive and I am pleased that he will continue to contribute to the growth of the business through dedicating his efforts to the French market."
For further information please contact:
Tristel plc | Via Walbrook PR | |
| Matt Sassone, Chief Executive Officer | ||
| Liz Dixon, Chief Financial Officer | | |
|
| | |
| Walbrook PR Ltd | Tel: 020 7933 8780 or tristel@walbrookpr.com | |
| Paul McManus | Mob: 07980 541 893 | |
| Charlotte Edgar | Mob: 07884 664 686 | |
| | | |
| Cavendish Capital Markets Limited | Tel: 020 7220 0500 | |
| Geoff Nash, Camilla Hume/Trisyia Jamaludin (Corporate Finance) | | |
| Sunila de Silva (Corporate Broking) | | |
The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation ("MAR") EU no.596/2014. Upon the publication of this announcement via Regulatory Information Service ("RIS"), this inside information is now considered to be in the public domain.
About Tristel plc
Tristel plc is a global infection prevention company focussed on the manufacture and supply of products using its unique proprietary chlorine dioxide (ClO2) chemistry. The Company is a market leader in manual decontamination of medical devices, supplying hospitals under the Tristel brand, and under the Cache brand provides products for sporicidal surface disinfection, in a format which is a sustainable alternative to commonly used pre-wetted plastic wipes.
Tristel's head office and manufacturing facility is located in Snailwell, near Cambridge, and operates globally employing approximately 250 people across 14 subsidiaries selling into 40 countries.
The Company has been listed on the London Stock Exchange's AIM market since 2005 (AIM: TSTL).
For more information about Tristel's product range please visit: https://tristel.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
